73

KU-55933

73 Publications Verification

Cat. No.: HY-12016

CAS No.: 587871-26-9

Purity: 99.92%

Target:

ATM/ATR Autophagy

Research Areas:

Cancer

KU-55933 is a potent ATM inhibitor with an IC₅₀ and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

21

Floxuridine

21 Cited Publications

Cat. No.: HY-B0097

CAS No.: 50-91-9

Synonyms: 5-Fluorouracil 2'-deoxyriboside

Target:

Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis

Research Areas:

Infection Cancer

Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

8

CGK733

8 Cited Publications

Cat. No.: HY-15520

CAS No.: 905973-89-9

Purity: 99.83%

Target:

ATM/ATR

Research Areas:

Cancer

CGK733 is a potent ATM/ATR inhibitor, used for the research of cancer.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Camonsertib

4 Cited Publications

Cat. No.: HY-139609

CAS No.: 2417489-10-0

Purity: 99.75%

Synonyms: RP-3500; ATR inhibitor 4

Target:

ATM/ATR mTOR

Research Areas:

Cancer

Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Lartesertib

4 Cited Publications

Cat. No.: HY-150617

CAS No.: 2495096-26-7

Purity: 99.94%

Synonyms: M4076; ATM Inhibitor-5

Target:

ATM/ATR STING PD-1/PD-L1

Research Areas:

Cardiovascular Disease Inflammation/Immunology Cancer

Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Alnodesertib

Cat. No.: HY-157941

CAS No.: 2267316-76-5

Purity: 99.89%

Synonyms: ART0380

Target:

ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis

Research Areas:

Cancer

ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC₅₀ of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Tilatamig samrotecan

Cat. No.: HY-171124

Synonyms: AZD9592

Target:

Antibody-Drug Conjugates (ADCs) EGFR c-Met/HGFR Topoisomerase DNA/RNA Synthesis

Research Areas:

Cancer

Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

AZ31

Cat. No.: HY-112198

CAS No.: 2088113-98-6

Purity: 98.13%

Target:

ATM/ATR

Research Areas:

Cancer

AZ31 is a a potent, highly selective, and orally active ATM inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

PROTAC ATR degrader-2

Cat. No.: HY-161615

CAS No.: 3010273-12-5

Target:

PROTACs ATM/ATR Apoptosis

Research Areas:

Inflammation/Immunology Cancer

PROTAC ATR degrader-2 is a selective ATR PROTAC degrader. PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ values of 22.9 nM and 34.5 nM, respectively. PROTAC ATR degrader-2 has an IC₅₀ of 29.6 nM against ATR, and its IC₅₀ values against ATM and PI3K are both greater than 2000 nM. PROTAC ATR degrader-2 induces apoptosis, DNA damage, and upregulates p53 expression. PROTAC ATR degrader-2 inhibits cancer cell proliferation through the kinase-independent function of ATR protein. PROTAC ATR degrader-2 is applicable to research related to acute myeloid leukemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

SKLB-197

Cat. No.: HY-144217

CAS No.: 2713577-16-1

Purity: 99.91%

Target:

ATM/ATR

Research Areas:

Cancer

SKLB-197 showed an IC₅₀ value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.

Compare

loading...